Alector Ends Q1 with $206.5M Runway, Revenue Drops 73% to $1M
ALEC•Alector ended Q1 with $206.5M cash runway into at least 2027 and saw collaboration revenue fall to $1.0M from $3.7M year-over-year. R&D expenses halved to $17.9M and G&A dropped to $8.1M, reflecting the recent reduction in force.
1. First Quarter 2026 Financial Results
Alector reported collaboration revenue of $1.0M for Q1, down from $3.7M a year earlier due to reduced manufacturing activity. Research and development expenses decreased to $17.9M from $33.6M, while general and administrative costs fell to $8.1M from $14.7M, driven by recent workforce reductions.
2. Pipeline Progress and IND Timelines
The company continues advancing its ABC-enabled programs, targeting an IND submission for AL037/AL137 anti-amyloid beta antibodies in Q1 2027. Preclinical studies for AL050 (GCase enzyme replacement) and AL064/AL164 tau siRNA have demonstrated robust brain penetration and target engagement, supporting progression toward human trials.
3. Cash Runway and Operational Outlook
With $206.5M in cash, cash equivalents and investments as of March 31, 2026, Alector projects funding into at least 2027. Management emphasizes the differentiated blood-brain barrier platform’s versatility and remains focused on advancing multiple modalities across Alzheimer’s and Parkinson’s disease programs.
